Zum Hauptinhalt springen

Hepatitiden

04. September 2017 | Hepatitiden

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial Forns, Xavier et al. The Lancet Infectious Dis…

04. September 2017 | Hepatitiden

Preisübersicht verfügbare HCV-DAA (Rabattverträge nicht berücksichtigt)

(hepatitisandmore.de, Stand 23. August 2017) http://www.hepatitisandmore.de/hepatitis_c/medikamente/preis_uebersicht.shtml

04. September 2017 | Hepatitiden

Pharmakotherapie der chronischen Hepatitis-C-Virus-Infektion und Krebsrisiko

Pharmakotherapie der chronischen Hepatitis-C-Virus-Infektion und Krebsrisiko Einfluss direkt antiviral wirksamer Medikamente auf die Entstehung und Rekurrenz des hepatozellulären Karzinoms Drug treatment for chronic hepatitis C infection and…

04. September 2017 | Hepatitiden

Hepatitis B and C in Eastern Europe and Central Asia: an epidemic and a response

Hepatitis B and C in Eastern Europe and Central Asia: an epidemic and a response Alliance for Public Health, 08.08.2017, Report in Russian. http://fileserver.idpc.net/library/Hepatitis-B-and-C-in-Eastern-Europe-and-Central-Asia-an-epidemic-and-a-r…

29. August 2017 | Hepatitiden

Ending HIV, hepatitis B, and hepatitis C: what about people with severe mental illness?

Ending HIV, hepatitis B, and hepatitis C: what about people with severe mental illness? Wainberg, Milton et al. The Lancet Psychiatry , Volume 4 , Issue 9 , 651 - 653 http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(17)30282-1/full…

29. August 2017 | Hepatitiden

NIDA: Women who inject drugs may be at greater risk of HCV than men

There is a clear body of research assessing sex and gender differences in risk behaviors among people who inject drugs, however little or no research has investigated sex differences in hepatitis C (HCV) susceptibility. A newly published analysis ex…

26. August 2017 | Hepatitiden

No Clinically Relevant Drug-Drug Interactions Between Methadone or Buprenorphine/Naloxone and Anti-Viral Combination Glecaprevir and Pibrentasvir.

No Clinically Relevant Drug-Drug Interactions Between Methadone or Buprenorphine/Naloxone and Anti-Viral Combination Glecaprevir and Pibrentasvir. Kosloski M, Zhao W, Asatryan A, Kort J, Geoffroy P, Liu W. Antimicrob Agents Chemother. 2017 Aug 14…

Weitere
akutelle Informationen
zu den Themengebieten